D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 58 Citations 10,900 233 World Ranking 6176 National Ranking 83

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Enzyme
  • Gene

Vladimir Tolmachev focuses on Affibody molecule, Cancer research, Molecular imaging, Biodistribution and Pathology. His Affibody molecule study combines topics from a wide range of disciplines, such as Molecular biology, Phage display and Peptide synthesis. The study incorporates disciplines such as Nuclear medicine, Antibody, Monoclonal antibody and Trastuzumab in addition to Cancer research.

His Molecular imaging study also includes

  • Computational biology and related Nanotechnology, Protein engineering and Molecule,
  • Radionuclide imaging which connect with Healthy subjects, Tissue distribution and Knee Joint. His study in Biodistribution is interdisciplinary in nature, drawing from both Radionuclide therapy, Immunology, Combinatorial chemistry, Oligopeptide and Histidine. His Pathology research includes themes of Ligand, Receptor, Pet imaging, Positron emission tomography and Breast cancer.

His most cited work include:

  • Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. (437 citations)
  • Tumor imaging using a picomolar affinity HER2 binding affibody molecule. (414 citations)
  • Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules (222 citations)

What are the main themes of his work throughout his whole career to date?

Vladimir Tolmachev mainly investigates Affibody molecule, Biodistribution, Cancer research, Molecular imaging and In vitro. The subject of his Affibody molecule research is within the realm of Biochemistry. Vladimir Tolmachev usually deals with Biodistribution and limits it to topics linked to Biophysics and Molecule and Stereochemistry.

His work in Cancer research addresses issues such as Monoclonal antibody, which are connected to fields such as Antigen. His Molecular imaging research incorporates themes from Cancer and Breast cancer. The concepts of his In vitro study are interwoven with issues in Molecular biology and Internalization.

He most often published in these fields:

  • Affibody molecule (33.33%)
  • Biodistribution (34.30%)
  • Cancer research (32.13%)

What were the highlights of his more recent work (between 2018-2021)?

  • Biodistribution (34.30%)
  • Cancer research (32.13%)
  • Molecular imaging (21.01%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Biodistribution, Cancer research, Molecular imaging, In vitro and Affibody molecule. His Biodistribution study incorporates themes from Cancer cell, Biophysics, Internalization and Pharmacology, Binding selectivity. Vladimir Tolmachev combines subjects such as Molecular medicine, Targeted therapy, DARPin, Prostate cancer and Monoclonal antibody with his study of Cancer research.

His Molecular imaging research is multidisciplinary, incorporating perspectives in Pet imaging, Breast cancer, Spect imaging and Molecular targets. The various areas that Vladimir Tolmachev examines in his Affibody molecule study include Contrast, DOTA, Magnetic resonance imaging, Cytotoxic T cell and Receptor expression. The DOTA study combines topics in areas such as Molecular biology and Receptor–ligand kinetics.

Between 2018 and 2021, his most popular works were:

  • Affibody Molecules as Targeting Vectors for PET Imaging (15 citations)
  • Affibody Molecules as Targeting Vectors for PET Imaging (15 citations)
  • Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. (13 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Enzyme
  • Gene

Vladimir Tolmachev mostly deals with Biodistribution, Molecular imaging, Cancer research, Biophysics and Scaffold protein. His Biodistribution research entails a greater understanding of In vitro. His study on Molecular imaging also encompasses disciplines like

  • Binding selectivity which connect with Single-photon emission computed tomography,
  • Molecule, which have a strong connection to Pet imaging, Her2 expression and Molecular targets.

His research investigates the connection between Cancer research and topics such as Prostate cancer that intersect with problems in Peptide synthesis, Peptide and Receptor. His research in Biophysics intersects with topics in Chelation and Affibody molecule. His research investigates the connection between Affibody molecule and topics such as Trimer that intersect with issues in Cancer.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

John Löfblom;Joachim Feldwisch;Vladimir Tolmachev;Jörgen Carlsson.
FEBS Letters (2010)

598 Citations

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Anna Orlova;Mikaela Magnusson;Tove L.J. Eriksson;Martin Nilsson.
Cancer Research (2006)

538 Citations

Selection and characterization of HER2/neu-binding affibody ligands.

Maria Wikman;Ann-Charlott Steffen;Elin Gunneriusson;Vladimir Tolmachev.
Protein Engineering Design & Selection (2004)

330 Citations

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

Richard P. Baum;Vikas Prasad;Dirk Müller;Christiane Schuchardt.
The Journal of Nuclear Medicine (2010)

302 Citations

Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule

Vladimir Tolmachev;Anna Orlova;Rikard Pehrson;Joakim Galli.
Cancer Research (2007)

232 Citations

Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors

Anna Orlova;Vladimir Tolmachev;Rikard Pehrson;Malin Lindborg.
Cancer Research (2007)

221 Citations

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

Jens Sörensen;Dan Sandberg;Mattias Sandström;Anders Wennborg.
The Journal of Nuclear Medicine (2014)

193 Citations

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

Jan Terje Andersen;Rikard Pehrson;Vladimir Tolmachev;Muluneh Bekele Daba.
Journal of Biological Chemistry (2011)

169 Citations

Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding Affibody molecule

Mikaela Friedman;Anna Orlova;Eva Johansson;Tove L. J. Eriksson.
Journal of Molecular Biology (2008)

169 Citations

Preparation and evaluation of (68)Ga-DOTA-hEGF for visualisation of EGFR expression in malignant tumours

Irina Velikyan;Åsa Liljegren Sundberg;Örjan Lindhe;A Urban Höglund.
The Journal of Nuclear Medicine (2005)

160 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Vladimir Tolmachev

Jason S. Lewis

Jason S. Lewis

Memorial Sloan Kettering Cancer Center

Publications: 41

Stefan Ståhl

Stefan Ståhl

Royal Institute of Technology

Publications: 40

Inger Sandlie

Inger Sandlie

University of Oslo

Publications: 22

Sanjiv S. Gambhir

Sanjiv S. Gambhir

Stanford University

Publications: 21

Otto C. Boerman

Otto C. Boerman

Radboud University Nijmegen

Publications: 18

Lena Claesson-Welsh

Lena Claesson-Welsh

Uppsala University

Publications: 18

Xiaoyuan Chen

Xiaoyuan Chen

National University of Singapore

Publications: 17

Serge Muyldermans

Serge Muyldermans

Vrije Universiteit Brussel

Publications: 17

Uwe Haberkorn

Uwe Haberkorn

German Cancer Research Center

Publications: 17

Wim J.G. Oyen

Wim J.G. Oyen

Humanitas University

Publications: 16

Anna M. Wu

Anna M. Wu

City Of Hope National Medical Center

Publications: 16

Arne Skerra

Arne Skerra

Technical University of Munich

Publications: 14

Markus Schwaiger

Markus Schwaiger

Technical University of Munich

Publications: 13

Andreas Kjaer

Andreas Kjaer

University of Copenhagen

Publications: 13

Sophia Hober

Sophia Hober

Royal Institute of Technology

Publications: 13

Per-Åke Nygren

Per-Åke Nygren

Royal Institute of Technology

Publications: 12

Something went wrong. Please try again later.